Paul O’Regan presenting our latest work on eTARGET with colleagues at the Cancer Research UK Manchester Institute’s annual meeting in Lancaster this week.

eTARGET is a digital solution to support real-time decisions for the TARGET* trial’s molecular tumour board.  Integrating clinical and next generation sequencing genomic data in eTARGET means that we now have a genomic dataset. This is rapidly becoming a research tool that can support interim analyses and explore mutation signatures in the TARGET patient population.

*Tumour chARacterisation to Guide Experimental Targeted therapy

Download our annual report see more of our research projects, clinical trials and technology solutions

References

  • Rothwell et al. Utility of ctDNA to support patient selection for early phase clinical trials: The TARGET Study. Nature Medicine.
  • Stevenson J, Ayub M, Dransfield S, et al. eTARGET: a digital science solution to integrate clinical and genomic data for the Manchester Molecular Tumour Board (MTB)
    ESMO Open 2018;3:doi: 10.1136/esmoopen-2018-EACR25.58
  • Linkto CRUK press release